WO2002024876A3 - Live influenza vaccine and method of manufacture - Google Patents

Live influenza vaccine and method of manufacture Download PDF

Info

Publication number
WO2002024876A3
WO2002024876A3 PCT/EP2001/011087 EP0111087W WO0224876A3 WO 2002024876 A3 WO2002024876 A3 WO 2002024876A3 EP 0111087 W EP0111087 W EP 0111087W WO 0224876 A3 WO0224876 A3 WO 0224876A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell culture
manufacture
viruses
virus
influenza vaccine
Prior art date
Application number
PCT/EP2001/011087
Other languages
French (fr)
Other versions
WO2002024876A2 (en
Inventor
Hermann Katinger
Andre Egorov
Boris Ferko
Julia Romanova
Dietmar Katinger
Original Assignee
Polymun Scient Immunbio Forsch
Hermann Katinger
Andre Egorov
Boris Ferko
Julia Romanova
Dietmar Katinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch, Hermann Katinger, Andre Egorov, Boris Ferko, Julia Romanova, Dietmar Katinger filed Critical Polymun Scient Immunbio Forsch
Priority to KR10-2003-7004257A priority Critical patent/KR20030061810A/en
Priority to AU2002223560A priority patent/AU2002223560B2/en
Priority to AU2356002A priority patent/AU2356002A/en
Priority to AT01985267T priority patent/ATE434035T1/en
Priority to US10/381,530 priority patent/US7494659B2/en
Priority to KR1020087010816A priority patent/KR100927517B1/en
Priority to CA2423038A priority patent/CA2423038C/en
Priority to JP2002529471A priority patent/JP5063852B2/en
Priority to CN018192068A priority patent/CN1582333B/en
Priority to EP01985267A priority patent/EP1358319B1/en
Priority to DE60139026T priority patent/DE60139026D1/en
Priority to DK01985267T priority patent/DK1358319T3/en
Publication of WO2002024876A2 publication Critical patent/WO2002024876A2/en
Publication of WO2002024876A3 publication Critical patent/WO2002024876A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a simple and efficient process for isolating viruses from various sources and for producing live attenuated influenza vaccines in a serum-free Vero cell culture under conditions where alterations in the surface antigens of the virus due to adpative selection are minimized or prevented. The process does not require purification of the virus-containing supernatant harvested from the cell culture nor post-incubation treatment of the viruses for HA activation. The invention further relates to influenza A and B master strain candidates and to vaccines made thereof.
PCT/EP2001/011087 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture WO2002024876A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR10-2003-7004257A KR20030061810A (en) 2000-09-25 2001-09-25 Live vaccine and method of manufacture
AU2002223560A AU2002223560B2 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture
AU2356002A AU2356002A (en) 2000-09-25 2001-09-25 Live vaccine and method of manufacture
AT01985267T ATE434035T1 (en) 2000-09-25 2001-09-25 LIVE INFLUENZA VACCINE AND METHOD FOR THE PRODUCTION THEREOF
US10/381,530 US7494659B2 (en) 2000-09-25 2001-09-25 Live attenuated influenza vaccine
KR1020087010816A KR100927517B1 (en) 2000-09-25 2001-09-25 Live vaccine
CA2423038A CA2423038C (en) 2000-09-25 2001-09-25 Live vaccine and method of manufacture
JP2002529471A JP5063852B2 (en) 2000-09-25 2001-09-25 Live vaccine and production method
CN018192068A CN1582333B (en) 2000-09-25 2001-09-25 Live vaccine and method of manufacture
EP01985267A EP1358319B1 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture
DE60139026T DE60139026D1 (en) 2000-09-25 2001-09-25 LIVING INFLUENZA VACCINE AND METHOD FOR ITS MANUFACTURE
DK01985267T DK1358319T3 (en) 2000-09-25 2001-09-25 Live influenza vaccine and its method of preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00120896 2000-09-25
EP00120896.6 2000-09-25

Publications (2)

Publication Number Publication Date
WO2002024876A2 WO2002024876A2 (en) 2002-03-28
WO2002024876A3 true WO2002024876A3 (en) 2003-08-28

Family

ID=8169944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011087 WO2002024876A2 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture

Country Status (12)

Country Link
US (1) US7494659B2 (en)
EP (1) EP1358319B1 (en)
JP (1) JP5063852B2 (en)
KR (2) KR100927517B1 (en)
CN (1) CN1582333B (en)
AT (1) ATE434035T1 (en)
AU (2) AU2002223560B2 (en)
CA (1) CA2423038C (en)
DE (1) DE60139026D1 (en)
DK (1) DK1358319T3 (en)
ES (1) ES2327103T3 (en)
WO (1) WO2002024876A2 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
WO1999064570A1 (en) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Novel methods and interferon deficient substrates for the propagation of viruses
AT409379B (en) 1999-06-02 2002-07-25 Baxter Ag MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
CN103540613A (en) * 2002-04-26 2014-01-29 米迪缪尼有限公司 Multi plasmid system for the production of influenza virus
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2398706T3 (en) 2002-07-09 2013-03-21 Baxter International Inc. Animal protein free medium for cell culture
EA009008B1 (en) * 2002-09-05 2007-10-26 Бавариан Нордик А/С Method for amplification of poxviruses
JP2006516193A (en) 2002-12-06 2006-06-29 アイシス・ファーマシューティカルス・インコーポレーテッド Rapid identification of pathogens in humans and animals
KR101357443B1 (en) 2003-02-25 2014-02-06 메디뮨 엘엘씨 Methods of producing inflenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP4558652B2 (en) 2003-06-20 2010-10-06 マイクロビクス・バイオシステムズ・インコーポレイテツド Improved virus production
US20120122099A1 (en) 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
WO2005062820A2 (en) 2003-12-23 2005-07-14 Medimmune Vaccines, Inc Multi plasmid system for the production of influenza virus
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
ES2641832T3 (en) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by setting digital thresholds
CA2822895A1 (en) 2004-05-25 2005-12-08 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
CN1993140A (en) 2004-06-01 2007-07-04 纽约大学西奈山医学院 Genetically engineered swine influenza virus and uses thereof
EP1771584A4 (en) * 2004-07-02 2010-01-27 Henry L Niman Copy choice recombination and uses thereof
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006088481A2 (en) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
JP5075120B2 (en) 2005-06-17 2012-11-14 サノフィ・パスツール Dengue fever cello type 2 attenuated strain
JP2009502137A (en) 2005-07-21 2009-01-29 アイシス ファーマシューティカルズ インコーポレイティッド Method for rapid identification and quantification of nucleic acid variants
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070087338A1 (en) * 2005-10-17 2007-04-19 Rangarajan Sampath Compositions for use in identification of influenza viruses
US20070212770A1 (en) 2006-01-04 2007-09-13 Baxter International Inc. Oligopeptide-free cell culture media
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
US9642907B2 (en) * 2006-05-12 2017-05-09 Bharat Biotech International Limited Stabilized liquid rotavirus vaccine composition
US7601356B2 (en) * 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101586968B1 (en) * 2006-08-09 2016-01-20 메디뮨 엘엘씨 Influenza hemagglutinin and neuraminidase variants
EP2064332B1 (en) 2006-09-14 2012-07-18 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
EP2126132B1 (en) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Methods for rapid foresnsic dna analysis
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2008157583A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
AU2008272051A1 (en) * 2007-07-03 2009-01-08 Cytopathfinder, Inc. Treatment of influenza
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
BRPI0915487A2 (en) * 2008-07-11 2017-06-27 Medimmune Inc nfluenza hemagglutin and neuraminidase variants
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
WO2010033599A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
WO2010033625A1 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
AU2010213966B2 (en) 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
BR112012000826B1 (en) 2009-07-06 2022-07-26 Variation Biotechnologies Inc METHOD FOR THE PREPARATION OF VESICLES
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US20110070254A1 (en) * 2009-07-10 2011-03-24 University Of Ottawa Mutations in the influenza a virus ns1 gene and use thereof
WO2011008971A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Lift and mount apparatus
WO2011008972A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Systems for bioagent identification
EP3225695A1 (en) 2009-10-15 2017-10-04 Ibis Biosciences, Inc. Multiple displacement amplification
WO2011151726A2 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
BR112013000394B8 (en) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Immunogenic composition, use thereof and method of preparing said composition
ES2630012T3 (en) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Freeze-dried viral formulations
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CN104302323A (en) 2012-01-12 2015-01-21 变异生物技术公司 Compositions and methods for treating viral infections
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN102660511B (en) * 2012-05-17 2013-08-21 肇庆大华农生物药品有限公司 Method for reducing pancreatin inhibitor in serum and application of serum
SG11201507454XA (en) * 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
CN104056276B (en) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 Influenza virus attenuated live vaccine and preparation method thereof
CN111500631B (en) 2013-10-28 2024-03-29 蓝天免疫疗法有限责任公司 Novel influenza virus vectors for viral therapy
MA41506A (en) * 2015-02-13 2017-12-19 Takeda Vaccines Inc VIRUS PRODUCTION PROCESSES TO PRODUCE VACCINES
AU2016222962B2 (en) 2015-02-26 2020-05-21 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
WO2018183426A1 (en) * 2017-03-30 2018-10-04 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
US11629338B2 (en) 2017-11-09 2023-04-18 Jianshun Biosciences Co., Ltd. Method for acclimating and suspending Vero and second order production process for virus
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
CN112143693A (en) * 2019-06-28 2020-12-29 杭州康万达医药科技有限公司 Method for producing virus and harvesting solution composition
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN117330750A (en) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 Method for screening early virus seed of new coronavirus and method for preparing vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064068A1 (en) * 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
WO2000015251A2 (en) * 1998-09-15 2000-03-23 Baxter Aktiengesellschaft Influenza virus vaccine composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064068A1 (en) * 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
WO2000015251A2 (en) * 1998-09-15 2000-03-23 Baxter Aktiengesellschaft Influenza virus vaccine composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
N. KAVERIN AT AL.: "Impairment of multicycle influenza growth in Vero (WHO) cells by loss of trypsin activity", J. VIROL., vol. 69, no. 4, 1995, pages 2700 - 2703, XP002163942 *
O. KISTNER AT AL.: "Development of a Vero cell derived influenza whole virus vaccine", DEV. BIOL. STAND., vol. 98,, 1999, pages 101 - 110, XP000909542 *
O. KISTNER ET AL.: "Development of a mammalian cell (Vero) derived candidate influenza virus vaccine", VACCINE, vol. 16, no. 9/10, 1998, pages 960 - 968, XP002163941 *
O.W. MERTEN ET AL.: "Production of Influenza virus in serum-free mammalian cell cultures", DEV. BIOL. STAND., vol. 98, 1999, pages 23 - 37, XP000990517 *

Also Published As

Publication number Publication date
AU2356002A (en) 2002-04-02
KR20080043891A (en) 2008-05-19
CA2423038C (en) 2012-03-13
CN1582333A (en) 2005-02-16
AU2002223560B2 (en) 2006-06-29
ATE434035T1 (en) 2009-07-15
DE60139026D1 (en) 2009-07-30
JP5063852B2 (en) 2012-10-31
KR20030061810A (en) 2003-07-22
US7494659B2 (en) 2009-02-24
ES2327103T3 (en) 2009-10-26
CA2423038A1 (en) 2002-03-28
WO2002024876A2 (en) 2002-03-28
JP2004509903A (en) 2004-04-02
CN1582333B (en) 2010-06-16
EP1358319B1 (en) 2009-06-17
US20040137013A1 (en) 2004-07-15
KR100927517B1 (en) 2009-11-17
DK1358319T3 (en) 2009-10-05
EP1358319A2 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
WO2002024876A3 (en) Live influenza vaccine and method of manufacture
HK1048434A1 (en) Influenza vaccine
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
MX2007007889A (en) Rescue of influenza virus.
HRP20120790T1 (en) Low-additive influenza vaccines
AR011216A1 (en) A VACCINE BASED ON SURFACE ANTIGENS AGAINST INFLUENZA, A METHOD FOR PREPARING IT, AND A METHOD FOR PREPARING SURFACE ANTIGEN PROTEINS FROM PROPAGATED INFLUENZA VIRUSES ON AN ANIMAL CELL CULTURE
DE3480005D1 (en) Novel viruses and vaccines
MY128999A (en) Purification of hbv antigens for use in vaccines
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2006045532A3 (en) Virosome particles comprising antigens from influenza virus and hepatitis b virus
ATE427119T1 (en) RECOMBINANT RABIES VACCINE AND METHOD FOR THE PRODUCTION AND USE THEREOF
ATE494377T1 (en) VACCINES AGAINST IPNV THAT ARE ISOLATED FROM Yeast CELLS
ATE489106T1 (en) VIRUS-LIKE PARTICLES, METHOD OF PRODUCTION AND IMMUNOGENIC COMPOSITIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002223560

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001985267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2423038

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037004257

Country of ref document: KR

Ref document number: 2002529471

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 018192068

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037004257

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10381530

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001985267

Country of ref document: EP